Page 4 - Confidence Interval News Today

1. In this randomized controlled trial, semaglutide was more effective in reducing heart failure-related symptoms and physical limitations in patients with obesity-related heart failure and type 2 diabetes mellitus (T2DM) than placebo. 2. Patients with obesity-related heart failure and T2DM exhibited greater weight loss with semaglutide than placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Heart

Meta-analysis of 11 phase 3 trials shows SGLT2 inhibitors reduce cardiovascular event risk by 9% across diverse patient populations.

A new analysis of the REDUCE-IT trial reveals the benefits of icosapent ethyl in reducing cardiovascular outcomes regardless of LDL-C levels.

Safia Chatur, MD, discusses the results of a PARADIGM-HF analysis at ACC.24 examining the effects of ARNI use across the updated 2024 KDIGO Risk Classifications.

Deepak Bhatt, MD, MPH, MBA, provides a recap of top trials and new data from the American College of Cardiology's 2024 Annual Scientific Session.

Muthiah Vaduganathan, MD, MPH, discusses a presentation from ACC.24 assessing the effects of dapagliflozin across a range of left ventricular hypertrophy from DELIVER.

Martin Maron, MD, discusses the results of the IMPROVE-HCM trial and how it informs the community on the potential of plozasiran.

Results of EMPACT-MI suggest use of empagliflozin was not associated with a statistically significant reduction in a composite of death and heart failure hospitalization.

CSL112 infusion did not reduce major cardiovascular events at 90 days but further analysis suggests patients with elevated LDL-C levels could derive significant benefit.

1. In this randomized controlled trial, omalizumab was superior to placebo in increasing the reaction threshold to food allergens among participants with multiple food allergies. 2. The most common adverse event associated with omalizumab was injection-site reaction. Evidence Rating Level: 1 (Excellent) Study Rundown: Food allergy affects approximately 10% of the population, many of whom